71887-28-0

Usage

Uses

Used in Chemical Synthesis:
Methyl 2-bromomethyl-3-methoxybenzoate is used as a synthetic intermediate for the creation of new compounds. Its functional groups allow for versatile reactions, making it a valuable component in the synthesis of various organic molecules.
Used in Pharmaceutical Industry:
Methyl 2-bromomethyl-3-methoxybenzoate is used as a building block in the development of pharmaceutical compounds. Its unique structure can be incorporated into drug molecules to enhance their properties, such as solubility, stability, or bioavailability.
Used in Material Science:
Methyl 2-bromomethyl-3-methoxybenzoate is used as a component in the synthesis of advanced materials, such as polymers or composites. Its functional groups can contribute to the formation of new materials with improved properties, such as strength, flexibility, or thermal stability.
Safety Precautions:
When handling Methyl 2-bromomethyl-3-methoxybenzoate, it is essential to follow appropriate laboratory safety protocols to prevent injury or adverse health effects. As with all specialty chemicals, safety precautions must be taken to ensure a safe working environment.

InChI:InChI=1/C10H11BrO3/c1-13-9-5-3-4-7(8(9)6-11)10(12)14-2/h3-5H,6H2,1-2H3

Upstream product

• 55289-06-0 3-methoxy-2-methylbenzoic acid 
• 603-80-5 3-hydroxy 2-methylbenzoic acid 
• 42981-93-1 3-methoxy-2-methylbenzoic acid methyl ester 

Downstream Products

• 366453-22-7 4-methoxyisoindolin-1-one 
• 697801-41-5 C₁₆H₁₅NO₃ 
• 145498-86-8 methyl 3-methoxy-2-cyanomethylbenzoate 
• 755014-12-1 methyl 2-(methylthiomethyl)-3-methoxybenzoate 
• 366453-21-6 4-hydroxyisoindolin-1-one 
• 90047-52-2 3-methoxy-o-xylene-α,α'-diol 
• 180461-61-4 3-methoxy phthalaldehyde 
• 28281-58-5 7-methoxyisobenzofuran-1(3H)-one 
• 1482522-87-1 3-[(2,4-difluoroaminophenyl)amino]-7-methoxydibenzo-[b,e]oxepin-11(6H)-one 
• 755014-22-3 3-methoxy-2-allyloxymethyl benzoate 
• 4792-33-0 4-methoxyphthalide 

Relevant academic research and scientific papers

NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.

Rapid generation of novel benzoic acid–based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study

A series of novel xanthine derivatives 2a-l incorporating benzoic acid moieties were rapidly generated by using strategy of scaffold-hopping from our previously reported scaffold uracil to xanthine, a scaffold of approved drug linagliptin. After systematic structure-activity relationship (SAR) study around benzoic acid moieties, 5 novel DPP-4 inhibitors with low picomolar potency range (IC50 50 value of 0.1 nM for DPP-4, showed 22-fold improvement in inhibitory activity compared to lead compound uracil 1, its activity was 45-fold more potent than alogliptin. 2e, 2f, 2i and 2k were selected for pharmacokinetic evaluation, and 2f and 2i showed the better pharmacokinetic profiles after iv administration, but poor oral bioavailability. To improve the oral pharmacokinetic profile, prodrug design approach was performed around 2f and 2i. Esters of 2f and 2i were synthesized and evaluated for stability, toxicity and pharmacokinetics. Compound 3e, the methyl ester of compound 2f, was identified to demonstrate good stability, low toxicity and improved oral bioavailability, with 3-fold higher blood concentration compared to 2f in rats. The following in vivo evaluations revealed 3e provided a sustained pharmacodynamics effect for 48h, and robustly improved glucose tolerance in normal ICR and db/db mice in dose-dependent manner. Chronic treatments investigations demonstrated that 3e achieved more beneficial effects on fasting blood glucose levels and glucose tolerance than alogliptin in type 2 diabetic db/db mice. The overall results have shown that compound 3e has the potential to efficacious, safety and long-acting treatment for T2DM.

Assessment of the regioselectivity in the condensation reaction of unsymmetrical o-phthaldialdehydes with alanine

One approach for the synthesis of isoindolinones, a privileged bioactive heterocyclic core structure, involves a condensation reaction of o-phthaldialdehydes with a suitable nitrogen-containing nucleophile. This fascinating reaction is revisited here in the context of the use of o-phthaldialdehydes that contain additional substituents in the aromatic ring leading to a detailed analysis of the regioselectivity of the reaction. Eleven monosubstituted o-phthaldialdehydes were synthesised and reacted with alanine. The regioselectivity observed across the eleven substrates led to the design of a disubstituted substrate that reacted with very high control. A gram-scale reaction followed by esterification gave one major regioisomer in high yield. In addition, the regioselectivity observed on reaction of two novel monodeuterated substrates led to an increased mechanistic understanding.

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

A series of analogs of the immunomodulary drugs lenalidomide (1) and pomalidomide (2), in which the amino group is replaced with various isosteres, was prepared and assayed for immunomodulatory activity and activity against cancer cell lines. The 4-methyl and 4-chloro analogs 4 and 15, respectively, displayed potent inhibition of tumor necrosis factor-α (TNF-α) in LPS-stimulated hPBMC, potent stimulation of IL-2 in a human T cell co-stimulation assay, and anti-proliferative activity against the Namalwa lymphoma cell line. Both of these analogs displayed oral bioavailability in rat.

Metabolically stable dibenzo[ b, e ]oxepin-11(6 H)-ones as highly selective p38 MAP kinase inhibitors: Optimizing anti-cytokine activity in human whole blood

Five series of metabolically stable disubstituted dibenzo[b,e]oxepin-11(6H) -ones were synthesized and tested in a p38α enzyme assay for their inhibition of tumor necrosis factor-α (TNF-α) release in human whole blood. Compared to the monosubstituted dibenzo[b,e]oxepin-11(6H)-one derivatives, it has been shown that the additional introduction of hydrophilic residues at position 9 leads to a substantial improvement of the inhibitory potency and metabolic stability. Using protein X-ray crystallography, the binding mode of the disubstituted dibenzoxepinones and the induction of a glyince flip in the hinge region were confirmed. The most potent compound of this series, 32e, shows an outstanding biological activity on isolated p38α, with an IC50 value of 1.6 nM, extraordinary selectivity (by a factor >1000, Kinase WholePanelProfiler), and low ATP competitiveness. The ability to inhibit the release of TNF-α from human whole blood was optimized down to an IC50 value of 125 nM. With the promising dibenzoxepinone inhibitor 3i, a pharmacokinetic study in mice was conducted.

Synthesis and antibacterial activity of pleuromutilin derivatives with novel C(14) side chain

In order to find novel antibacterial agents with superior antibacterial activity and overcoming multidrug resistance, a series of pleuromutilin derivatives with novel C(14) side chain were synthesized and evaluated for their in vitro antibacterial activit

Design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates

We report herein the design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates based on the structure of SB-222734. The antibacterial activities of these newly synthesized compounds were also evaluated and compared with linezolid and retapamulin. Results showed that most of the target compounds exhibit good potency in inhibiting the growth of Gram-positive bacteria including Methicillin- susceptible Staphylococcus aureus MSSA (MIC: 0.0625-2 μg/mL), Methicillin-resistant S. aureus MRSA (MIC: 0.0625-2 μg/mL), Methicillin-susceptible Staphylococcus epidermidis MSSE (MIC: 0.0625-2 μg/mL), Methicillin-resistant S. epidermidis MRSE (MIC: 0.0625-2 μg/mL), and Streptococcus pneumonia (MIC: 0.0625-4 μg/mL). In particular, three remarkable compounds of this series (12l, 12m, and 21l) exhibited comparable in vitro antibacterial profiles to that of retapamulin.

Diiron complexes with pendant phenol group(s) as mimics of the diiron subunit of [FeFe]-hydrogenase: Synthesis, characterisation, and electrochemical investigation

Four diiron hexacarbonyl complexes, [Fe2(μ-SCH 2-o-C6H4OMe)2(CO)6] (4a), [Fe2{μ-SCH2-o,m-C6H3(OMe) 2}2-(CO)6] (4b), [Fe2{μ-SCH 2-o,o′-C6H3(CO2Me)(OMe)} 2(CO)6] (4c) and the demethylated form of complex 4a, [Fe2(μ-SCH2-o-C6H4OH) 2(CO)6] (5a), were synthesised and fully characterised. Complexes 4b and 4c were also structurally analysed. Electrochemical investigations revealed that the integrity of the bridging linkages of the examined diiron complexes significantly affect their reduction reversibility and catalysis through a coupled chemical reaction in a unique ECE mechanism, widely adopted by complexes with the core {Fe2(CO)4-6}. Demethylation of complexes 4a and 1Me, [Fe2(μ-SCH 2)2CMe(CH2-o-C6H4OMe)(CO) 6], by BBr3 led to complexes (5a and 1H, [Fe 2(μ-SCH2)2CMe(CH2-o-C 6H4OH)-(CO)6]) with pendant phenol group(s), a weak acid. Deprotonation of the two complexes produced the pendant phenolate, which instantly intramolecularly substitutes the bound CO to yield species of the coordination form FeI-OR (R = phenolic moiety). Electrochemical investigation revealed that the pendant phenol groups in complexes 1H and 5a do not seem to improve their catalytic efficiency in proton reduction in the medium acetic acid/dichloromethane.

Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex

The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Compounds represented by formula (1), wherein R1 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, and haloalkyl; R2 is H or methyl; R3 is H or (C1-4)alkyl; R4 is H or (C1-4)a